Abstract
Brain-derived neurotrophic factor (BDNF) is one of the candidate genes for schizophrenia. Polymorphism C-281A (rs28383487) in BDNF gene leads to the reduction of promoter activity in the hippocampal neurons in vitro. To our knowledge, this is the first study to examine the influence of alleles and genotypes of BDNF C-281A polymorphism on development, as well as the clinical course (age of onset, suicidal behaviour and psychopathology) of paranoid schizophrenia. The psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS) as subscale scores and also single-item scores. We have also performed the haplotype analysis with val66met BDNF polymorphism, which is known to be involved in the pathogenesis of schizophrenia. We have not found significant differences in the distribution of genotypes and alleles between schizophrenic patients and controls in both the overall analysis, as well as sex stratified. Also, we have not shown statistically significant differences between genotype groups and PANSS scale. However, an association between C-281A polymorphism and time of the first episode of paranoid schizophrenia was revealed. Genotype C/A had been connected with later age of onset of paranoid schizophrenia in men but not in women (p < 0.01). The C-281A and val66met polymorphisms have been in a strong linkage disequilibrium (D′ = 0.9875; p < 0.05). The haplotype analysis has shown a tendency to a significantly lower frequency of the Met-C haplotype in the schizophrenia group compared to the controls.
References
Belcher SM, Zsarnovszky A (2001) Estrogenic actions in the brain: estrogen, phytoestrogens, and rapid intracellular signaling mechanisms. J Pharmacol Exp Ther 299:408–414
Bradley AJ, Dinan TG (2010) A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality. J Psychopharmacol 24(4 Suppl):91–118
Chang HA, Lu RB, Shy MJ, Chang CC, Lee MS, Huang SY (2009) Brain-derived neurotrophic factor Val66Met polymorphism: association with psychopathological symptoms of schizophrenia? J Neuropsychiatry Clin Neurosci 21:30–37
Chao MV, Rajagopal R, Lee FS (2006) Neurotrophin signalling in health and disease. Clin Sci (Lond) 110(2):167–173
Chen DC, Wang J, Wang B et al (2009) Decreased levels of serum brain-derived neurotrophic factor in drug-naïve first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl) 207:375–380
Craddock N, O'Donovan MC, Owen MJ (2005) The genetics of schizophrenia and bipolar disorder: dissecting psychosis. J Med Genet 42:193–204
Dell'osso L, Carmassi C, Del Debbio A, Dell'osso MC, Bianchi C, da Pozzo E et al (2009) Brain-derived neurotrophic factor plasma levels in patients suffering from post-traumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry 33(5):899–902
Dwivedi Y (2010) Brain-derived neurotrophic factor and suicide pathogenesis. Ann Med 42:87–96
Fatemi SH, Folsom TD (2009) The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 35(3):528–548
Guillin O, Demily C, Thibaut F (2007) Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine. Int Rev Neurobiol 78:377–395
Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN et al (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25(2):372–383
Huang TL, Lee CT (2006) Associations between serum brain-derived neurotrophic factor levels and clinical phenotypes in schizophrenia patients. J Psychiatr Res 40(7):664–668
Issa G, Wilson C, Terry AV Jr, Pillai A (2010) An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis 39(3):327–333
Jiang X, Xu K, Hoberman J, Tian F, Marko AJ, Waheed JF et al (2005) BDNF variation and mood disorders: a novel functional promoter polymorphism and Val66Met are associated with anxiety but have opposing effects. Neuropsychopharmacology 30(7):1353–1361
Kirov G, O'Donovan MC, Owen MJ (2005) Finding schizophrenia genes. J Clin Invest 115:1440–1448
Kumamaru E, Numakawa T, Adachi N, Yagasaki Y, Izumi A, Niyaz M et al (2008) Glucocorticoid prevents brain-derived neurotrophic factor-mediated maturation of synaptic function in developing hippocampal neurons through reduction in the activity of mitogen-activated protein kinase. Mol Endocrinol 22(3):546–558
Kunugi H, Hori H, Adachi N, Numakawa T (2010) Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci 64:447–459
Luellen BA, Bianco LE, Schneider LM, Andrews AM (2007) Reduced brain-derived neurotrophic factor is associated with a loss of serotonergic innervation in the hippocampus of aging mice. Genes Brain Behav 6:482–490
Müller MJ (2007) Gender-specific associations of depression with positive and negative symptoms in acute schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31(5):1095–1100
Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P et al (2005) BDNF gene is a risk factor for schizophrenia in a Scottish population. Mol Psychiatry 10(2):208–212
Numakawa T, Kumamaru E, Adachi N, Yagasaki Y, Izumi A, Kunugi H (2009) Glucocorticoid receptor interaction with TrkB promotes BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate transporter. Proc Natl Acad Sci USA 106(2):647–652
Schumacher J, Jamra RA, Becker T, Ohlraun S, Klopp N, Binder EB et al (2005) Evidence for a relationship between genetic variants at the brain-derived neurotrophic factor (BDNF) locus and major depression. Biol Psychiatry 58(4):307–314
Shalev I, Lerer E, Israel S, Uzefovsky F, Gritsenko I, Mankuta D et al (2009) BDNF Val66Met polymorphism is associated with HPA axis reactivity to psychological stress characterized by genotype and gender interactions. Psychoneuroendocrinology 34(3):382–388
Sohrabji F, Lewis DK (2006) Estrogen-BDNF interactions: implications for neurodegenerative diseases. Front Neuroendocrinol 27(4):404–414
Suchanek R, Owczarek A, Kowalczyk M, Kucia K, Kowalski J (2011) Association between C-281A and Val66met functional polymorphisms of BDNF gene and risk of recurrent major depressive disorder in Polish population. J Mol Neurosci 43(3):524–530
Tost H, Alam T, Meyer-Lindenberg A (2010) Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes. Neurosci Biobehav Rev 34:689–700
Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ (2006) Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9(4):519–525
Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE (2003) Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry 8(6):592–610
Zhou DH, Yan QZ, Yan XM, Li CB, Fang H, Zheng YL et al (2010) The study of BDNF Val66Met polymorphism in Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 34(6):930–933
Acknowledgement
We would like to thank MSc Eng Paweł Raif from Silesian University of Technology for help in interpreting the statistical analyses.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Suchanek, R., Owczarek, A. & Kowalski, J. Association Study Between BDNF C-281A Polymorphism and Paranoid Schizophrenia in Polish Population. J Mol Neurosci 46, 217–222 (2012). https://doi.org/10.1007/s12031-011-9582-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-011-9582-7